World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
-
* Corresponding author: Ric N Price ricprice@doctors.org.uk
Malaria Journal 2007, 6:119 doi:10.1186/1475-2875-6-119
Accesses
- Last 30 days: 116 accesses
- Last year: 1219 accesses
- All time: 7222 accesses
Cited by
BioMed Central: 5 citations
|
Research
Julien Zwang, Piero Olliaro, Hubert Barennes, Maryline Bonnet, Philippe Brasseur, Hasifa Bukirwa, Sandra Cohuet, Umberto D'Alessandro, Abdulaye Djimdé, Corine Karema, Jean-Paul Guthmann, Sally Hamour, Jean-Louis Ndiaye, Andreas Mårtensson, Claude Rwagacondo, Issaka Sagara, Albert Same-Ekobo, Sodiomon B Sirima, Ingrid van den Broek, Adoke Yeka, Walter RJ Taylor, Grant Dorsey, Milijaona Randrianarivelojosia Malaria Journal 2009, 8:203 (23 August 2009) This multi-center analysis study addresses efficacy of artesunate-amodiaquine, a very important candidate for the treatment of uncomplicated malaria globally. The analysis of patient-level data examining the efficacy of AS&AQ compared to local standard therapy, makes a strong case for the use of AS&AQ in all transmission settings.
|
|
Research
Maryline Bonnet, Ingrid van den Broek, Michel van Herp, Pedro Urrutia, Chantal van Overmeir, Juliet Kyomuhendo, Célestin Ndosimao, Elizabeth Ashley, Jean-Paul Guthmann Malaria Journal 2009, 8:192 (10 August 2009) The finding of varying efficacy of the same combinations at two sites in one country highlights one difficulty of implementing a uniform national treatment policy in a large country. The poor efficacy of AS+AQ in Boende should alert the national programme to foci of resistance and emphasizes the need for systems for the prospective monitoring of treatment efficacy at sentinel sites in the country.
|
|
Research
The effect of varying analytical methods on estimates of anti-malarial clinical efficacy Wendy J Verret, Grant Dorsey, Francois Nosten, Ric N Price Malaria Journal 2009, 8:77 (22 April 2009) Anti-malarial drug clinical trials are conducted both to monitor anti-malarial drug resistance and to compare treatment regimens. Estimates of anti-malarial clinical efficacy vary significantly depending on the analytical methodology from which they are derived. This paper compares different ways to estimate the risk of failure in 65 treatment arms from 29 clinical trials.
|
|
Methodology
Elizabeth A Ashley, Loretxu Pinoges, Eleanor Turyakira, Grant Dorsey, Francesco Checchi, Hasifa Bukirwa, Ingrid van den Broek, Issaka Zongo, Pedro Urruta, Michel van Herp, Suna Balkan, Walter R Taylor, Piero Olliaro, Jean-Paul Guthmann Malaria Journal 2008, 7:154 (9 August 2008) Data from different in vivo studies of ACT treatment of uncomplicated falciparum malaria were combined in a single database. Efficacy at day 28 corrected by PCR genotyping was estimated using four methods.
|
|
Review
World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology Karen I Barnes, Niklas Lindegardh, Olumide Ogundahunsi, Piero Olliaro, Christopher V Plowe, Milijaona Randrianarivelojosia, Grace O Gbotosho, William M Watkins, Carol H Sibley, Nicholas J White Malaria Journal 2007, 6:122 (6 September 2007) This article is part of a collection on The world antimalarial... The determinants of treatment response are multi-factorial, but reaching adequate blood concentrations is pivotal to cure. Pharmacokinetic data can inform on optimal dosing, but only small number of patients have been studied, with even less conducted in the most vulnerable populations. A better understanding of the pharmacokinetic properties of antimalarials and a more clear definition of what constitutes “therapeutic drug levels” would allow more precise use of the term “antimalarial resistance”, as it would indicate when treatment failure is not caused by intrinsic parasite resistance but is the result of inadequate drug levels.
|